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Abstract
Epidemiological data suggest an association between kidney stones and some features of metabolic syndrome such as an overweight
condition, arterial hypertension or glucose intolerance. However, mechanisms remain to be elucidated. This study aimed to evaluate insulin
resistance, as assessed by homeostasis model assessment (HOMA-IR), and urine composition analysis in patients affected by calcium nephro-
lithiasis. A cohort of 61 (38 male, 29e57 years of age) non-diabetic calcium stone formers was studied. Data about body mass index, arterial
blood pressure, serum biochemistry including parathyroid hormone and calcitriol were recorded in all the patients; fasting glucose and insulin
were determined to calculate HOMA-IR value and accordingly the patients were grouped into tertiles. Urine pH and urinary excretion of cal-
cium, citrate, phosphate, oxalate, uric acid, urea and creatinine were measured on 24 h urine samples. Patients of the highest HOMA-IR tertile
showed lower urine citrate levels than patients of the lowest HOMA-IR tertile (475  243 vs. 630  187 mg/24 h, p < 0.05), whereas no dif-
ference was detected as far as urinary oxalate, calcium, uric acid, phosphate, and urine pH and urine volume output were concerned. HOMA-IR
values were positively related to uric acid serum levels (r ¼ 0.31, p < 0.05) and negatively to urinary citrate excretion (r ¼ 0.26, p < 0.05).
Hypocitraturic patients showed higher levels of HOMA-IR than normocitraturic ones (3.03  0.92 vs. 2.25  1.19, p < 0.05). This study shows
that a higher level of insulin resistance is associated with lower urinary citrate excretion, and that hypocitraturic patients show a greater insulin
resistance than normocitraturic calcium stone formers. This may be related to changes in citrate, NaþeKþ and Hþ renal tubule transports, which
have been described in insulin resistance. In conclusion, insulin resistance may contribute to an increased risk of calcium stone formation by
lowering urinary citrate excretion. This finding suggests the need for a careful metabolic assessment in patients known to form calcium stones in
order to ensure stone recurrence prevention and cardiovascular protection.
 2006 Elsevier Masson SAS. All rights reserved.
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Calcium nephrolithiasis is a quite frequent disease in devel-
oped countries. Approximately 10% of men and 5% of women
will experience a symptomatic kidney stone by the age of
75 years and about 80% of kidney stones contain calcium
[1e3]. The identification of risk factors for nephrolithiasis
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doi:10.1016/j.biopha.2006.09.012may be helpful in the primary and secondary prevention of
kidney stone formation [4e6]. Epidemiological studies report
an association between nephrolithiasis and diabetes, obesity,
overweight [7e9] or arterial hypertension [10,11], but most
of the studies did not give information about the stone compo-
sition. However, the majority of patients were presumably af-
fected by calcium stone disease, since it is largely the most
frequent type in nephrolithiasis adult patients. In Western
countries, a growing population is affected by obesity and/or
metabolic syndrome, a condition defined by the clustering of
abdominal obesity, dyslipidaemia, elevated blood pressure,d.
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condition is associated also with hyperuricaemia, coronary ar-
tery disease and sympathetic overactivity, resulting in a higher
rate of cardiovascular events [12,13]. The metabolic syndrome
is considered a condition of insulin resistance.
When the different types of stone composition are taken
into account, evidence exists that insulin resistance is associ-
ated with uric acid stone disease [14]. This is in keeping
with some reports showing that uric stone formers are more
frequently hypertensive and overweight, while exhibiting
higher plasma levels of both triglycerides and uric acid
[15,16].
The association between insulin resistance and uric acid
stone disease [14] can be explained by a defect in urine acid-
ification, namely to an impaired L-glutamine system and re-
duction of NaþeKþ transport at the proximal tubule. This
change results in very low urine pH which is the main risk fac-
tor for uric acid stone formation. A defect of the NaþeKþ and
Hþ transport systems could also be associated with lower cit-
rate excretion, which is a well known risk factor for calcium
stone formation [4e6]. In addition, insulin may also affect
renal handling of calcium and phosphate, which are factors
implicated in calcium stone formation as well [17e19]. This
study aimed to evaluate the association between risk factors
for calcium stone formation and insulin resistance in a cohort
of non-diabetic calcium stone formers.
2. Patients and methods
Sixty-one non-diabetic calcium stone formers (38 males, 23
females, 29e57 years of age) were included in the study. Di-
agnosis was proven by chemical analysis of passed stones or
by the detection of Rx-opaque kidney stones. Patients with
uric acid, struvite or cystine stones or with urinary tract infec-
tion were excluded. Renal tubular acidosis, primary hyper-
parathyroidism or sarcoidosis were considered as exclusion
criteria, as well as chronic liver disease, renal insufficiency
or chronic pancreatitis. No patient was on steroid or immuno-
suppressive therapy. At the time of the study, the patients were
studied without any drugs able to interfere with calcium or cit-
rate excretion, namely no patient assumed diuretics or potas-
sium citrate. Some hypertensive patients were on therapy
with calcium-channel blockers (5 cases), ACE-inhibitors or
angiotensin II receptor blockers (6 cases), or beta-blockers
(3 cases).
We have not systematically performed dietary records in all
the patients. However, our cohort is quite homogeneous for
race and lifestyle, presuming that the majority followed a
Mediterranean diet, with a mean sodium intake of 197 
97 mmol/24 h.
The history of the patients selected for the study showed
a single stone episode in 21 of them. In the patients with recur-
rences, the rate was 0.39 stones/patient per year, before our
observation.
Blood samples were taken after an overnight fasting to
measure serum levels of creatinine, urea, uric acid, calcitriol,
parathyroid hormone (PTH), glucose, calcium, phosphate,alkaline phosphates, magnesium, sodium, potassium, total
cholesterol, high-density lipoprotein (HDL) cholesterol, and
triglycerides. Fasting levels of insulin were determined using
an immunoradiometric assay (DiaSorin, Italy). Insulin resis-
tance was assessed using the validated homeostasis model as-
sessment (HOMA-IR) [20], based on fasting immunoreactive
insulin and glucose plasma levels. It was calculated by the
following formula: HOMA-IR ¼ fasting immunoreactive in-
sulin (mU/ml) * fasting glucose (mmol/l)/22.5. It is assumed
that low HOMA-IR values mean normal insulin sensitivity
whereas high values mean insulin resistance. According to ter-
tiles of HOMA-IR values, the studied population was divided
into three groups with low, middle and high HOMA-IR
values.
Samples from 24 h urine collections, using thymol as preser-
vative, were used to measure daily urinary excretion of calcium,
citrate, phosphate, oxalate, urea, creatinine and pH. We defined
hypercalciuria as a daily urinary calcium excretion > 4 mg/kg
body weight, hyperoxaluria as a urinary oxalate > 42 mg/day,
hyperuricuria as an uric acid excretion > 700 mg in males and
600 mg in females. Hypocitraturia was defined as an urinary
citrate excretion of <320 mg/day.
Urinary oxalate was determined by an enzymatic method
using oxalate oxidase, and urinary citrate was assayed by the
citrate lyase method, after sample centrifugation for separation
of insoluble substances. All the other determinations were
assessed using the routine laboratory methods.
Dietary protein intake was calculated using the urea appear-
ance method according to Maroni’s formula [21], and expressed
as protein catabolic rate normalized by kg of body weight
(nPCR).
2.1. Statistical analysis
Descriptive statistics are expressed as mean  standard de-
viation. Statistical evaluation was performed using a statistical
package (Excel for Windows) for personal computer. Differ-
ences between groups were evaluated by the Student’s t-test
for unpaired data, and the one-way analysis of variance
(one-way ANOVA). Pearson’s correlation test and multivariate
regression analysis were performed. Statistical differences
were considered significant when p < 0.05.
3. Results
In the studied population, the prevalence of the main
metabolic risk factors of calcium stone disease resulted the
following: 28% hypercalciuria, 25% hypocitraturia, 20% hy-
peruricosuria and 11% hyperoxaluria. In the same patient,
hypercalciuria was associated with hypocitraturia in 3 cases,
with hyperuricosuria in 6 cases and with hyperoxaluria in 2
cases. No patient showed more than two of these conditions
associated.
Eleven percent of patients were overweight, and 9%
showed a BMI > 30 kg/m2.
Patients in the highest HOMA-IR tertiles showed lower
citrate levels than patients in the middle or the lowest tertile
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HOMA-IR groups as far as urinary oxalate, calcium, uric
acid and phosphate were concerned. As expected, the highest
HOMA-IR tertile showed higher fasting serum levels of insu-
lin and uric acid. Accordingly, correlation analysis demon-
strated that HOMA-IR values were positively related to uric
acid serum levels (r ¼ 0.31, p < 0.05) and negatively to uri-
nary citrate excretion (r ¼ 0.26, p < 0.05) (Fig. 1). No statis-
tically significant correlation resulted between HOMA-IR and
the other urinary parameters studied.
Patients with hypocitraturia showed higher levels of
HOMA-IR values than patients with normal values
(3.03  0.92 vs. 2.25  1.19, p < 0.05); nine out of the 20
Table 1
Clinical and biochemical characteristics of the patients of the highest HOMA-
IR tertile and of the lowest HOMA-IR tertile
High HOMA-IR Low HOMA-IR p
Age, years 40.8  11.9 42.6  13.6 n.s.
Body weight, kg 74.4  16.6 73.5  19.5 n.s.
BMI, kg/m2 25.8  4.6 24.7  4.7 n.s.
nPCR, g/kg/body wt 1.1  0.2 1.1  0.2 n.s.
Systolic BP, mmHg 131.2  18.6 126.6  15.9 n.s.
Diastolic BP, mmHg 82.0  9.3 81.5  7.4 n.s.
Serum
Potassium, mEq/l 3.8  0.3 3.9  0.3 n.s.
Calcium, mg/dl 9.4  0.5 9.4  0.3 n.s.
Phosphate, mg/dl 3.3  0.6 3.1  0.7 n.s.
Uric acid, mg/dl 6.3  1.3 5.2  1.1 <0.01
PTH, pg/ml 31.8  18.1 35.7  18.8 n.s.
1,25-Vitamin D, pg/ml 50.5  21.4 53.1  18.3 n.s.
Insulin, mU/ml 16.0  3.4 6.3  1.6 <0.001
Glucose, mg/dl 96  13 87  7 <0.01
Triglycerides, mg/dl 136  64 129  75 n.s.
HDL cholesterol, mg/dl 50  10 59  12 <0.05
Total cholesterol, mg/dl 221  39 212  34 n.s.
HOMA-IR, insulin resistance as assessed by homeostasis model assessment;
BMI, body mass index; nPCR, normalized protein catabolic rate; BP, blood
pressure; PTH, parathyroid hormone; HDL, high-density lipoprotein; n.s.,
not significant.
r =- 0.26,    p<0.05
0
1
2
3
4
5
6
7
0 200 400 600 800 1000 1200
urinary citrate, mg/24h
H
O
M
A-
IR
Fig. 1. Relationship between urinary citrate excretion and insulin resistance, as
assessed by homeostasis model assessment (HOMA-IR), in the 61 patients
with calcium stone disease.patients of the highest HOMA-IR tertile were hypocitraturic
versus no patients from the lowest tertile (Table 2).
4. Discussion
Epidemiologic studies show that the incidence of nephroli-
thiasis increases in patients exhibiting an overweight condi-
tion, hypertension, dyslipidaemia and glucose intolerance. In
patients with uric acid stone disease, evidence exists that the
relationship between kidney stone formation and insulin resis-
tance is represented by reduced proximal tubule ammoniagen-
esis and marked decrease of urine pH. However, up to now
few data exist in the literature about the relationship between
urine composition and insulin resistance in calcium-stone
formers.
The results of our study show that higher insulin resistance
is associated with lower urinary citrate excretion, and that hy-
pocitraturic patients show a higher insulin resistance than nor-
mocitraturic patients. Instead, protein intake, body mass index,
renal function, serum PTH, calcitriol, and the urinary excre-
tion of calcium, uric acid, oxalate and phosphate were quite
similar among the three groups of patients with different
HOMA-IR values. Our data suggest that insulin resistance
may contribute to calcium stone formation by reducing urinary
citrate excretion. The lower citrate excretion in the presence of
insulin resistance may be caused by a defect in renal ammo-
nium production or by changes in NaþeKþ and Hþ transport
mechanisms of the renal tubules [8,14]. Patients with insulin
resistance have high levels of plasma free fatty acids, which
can enter the proximal tubule cells and interfere with the uti-
lization of glutamine; since free fatty acids constitute an alter-
native metabolic substrate for the proximal tubule cells, it
results a reduction in glutamine usage and ammoniagenesis
[22e24]. In addition, insulin resistance may directly impair
ammoniagenesis as demonstrated by in vitro studies which
showed that insulin is able to stimulate renal ammonium pro-
duction from L-glutamine [25,26]. Insulin may also play a role
in the activity of the proximal renal tubule Na/K exchanger in-
volved in transport or ionic trapping of ammonium in the tubular
lumen [27]. Thus patients with insulin resistance may have an
impaired ability to excrete ammonia so leading to hyperacidic
urine [14], the main risk factor for uric acid stone formation
Table 2
Renal function and urine composition characteristics of the patients of the
highest HOMA-IR tertile and of the lowest HOMA-IR tertile
High HOMA-IR Low HOMA-IR p
Urine
Volume output, ml/24 h 1839  634 2065  573 n.s.
pH 5.7  0.4 5.7  0.5 n.s.
Calcium, mg/24 h 231  115 264  129 n.s.
Phosphate, mg/24 h 815  344 792  213 n.s.
Oxalate, mg/24 h 24.6  7.1 25.9  4.4 n.s.
Citrate, mg/24 h 475  243 630  187 <0.05
Uric acid, mg/24 h 565  258 555  200 n.s.
Creatinine, mg/24 h 1594  508 1585  379 n.s.
Creatinine clearance, ml/min 119  33 113  27 n.s.
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citrate, i.e. it can increase apical membrane citrate uptake as
long as citrate metabolism is highly maintained, leading to hy-
pocitraturia, which is a major risk factor for calcium stone for-
mation [4e6].
We have not observed any difference in calcium excretion.
However, evidence exists that the compensatory hyperinsuli-
naemia of insulin resistance may increase urinary calcium
excretion [17,18] by decreasing the tubular reabsorption of
filtered calcium [28], favouring urinary oversaturation for
calcium phosphate and calcium oxalate.
In summary, our data show that a greater level of insulin re-
sistance is associated with lower urinary citrate excretion, and
that hypocitraturic patients show more insulin resistance than
normocitraturic patients. This may be related to changes in cit-
rate, NaþeKþ and Hþ transport of the renal tubule, which has
been described in conditions of insulin resistance. A larger
cohort of patients and more sensitive methods to assess in-
sulin resistance will be needed to confirm the association we
observed between insulin resistance and low urine citrate in
calcium stone patients.
It can be speculated that insulin resistance is more likely as-
sociated with uric stone formation when defective urinary
acidification results in changes in urine pH, namely hyperaci-
dic urine, whereas it is more likely associated with calcium
stone formation when a decrease of urinary citrate excretion
occurs without significant reduction of urine pH.
In the present study, the insulin resistance was estimated by
HOMA-IR and not by euglycaemic hyperinsulinaemic clamp:
this may be considered as a limitation of the study. However,
a fairly good correlation exists between HOMA-IR and clamp-
derived measures in adults [30], pregnancy [31] and renal
dysfunction [32], suggesting that HOMA-IR may be a quite
simple and useful tool for the screening of insulin resistance
in a clinical setting and in population studies.
In conclusion, this study shows an association between the
HOMA-IR values and changes in urinary citrate excretion in
calcium stone formers. It can be speculated that insulin resis-
tance may contribute, in part at least, to lowering urinary cit-
rate excretion and thus to an increased risk of stone formation.
This finding suggests the need for a careful metabolic assess-
ment in patients known to form kidney stones in order to en-
sure effective stone recurrence prevention and cardiovascular
protection.
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